# Alessandro Gronchi

Source: https://onco.cc/people/alessandro-gronchi/  
OnCo record `alessandro-gronchi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.

## Summary

Alessandro Gronchi is Chair of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, a surgeon whose specialisms are sarcoma surgery, retroperitoneal sarcoma and neoadjuvant chemotherapy. He is known for chairing ISG-STS 1001, the randomised trial that compared histology-tailored neoadjuvant chemotherapy with standard chemotherapy in high-risk soft-tissue sarcoma, and STRASS, which tested preoperative radiotherapy. His Lancet Oncology paper on ISG-STS 1001 set out how tailoring chemotherapy to sarcoma histotype compares with a standard regimen. He continues to lead the sarcoma surgical programme at INT Milan, with his publications listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chair, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori
- Specialisms: Sarcoma surgery; Retroperitoneal sarcoma; Neoadjuvant chemotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Gronchi%20A%5BAuthor%5D%20sarcoma

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [European Society of Surgical Oncology](https://onco.cc/institutions/esso/), [Fondazione IRCCS Istituto Nazionale dei Tumori](https://onco.cc/institutions/int-milan/)
- trials: [ISG-STS 1001](https://onco.cc/trials/isg-sts-1001/)
- ideas: [A same-week expert second opinion for every rare cancer diagnosis](https://onco.cc/ideas/idea-bio2-rare-cancer-telepathology-network/)

---
JSON: https://onco.cc/api/v1/entities/alessandro-gronchi.json